10-Q: Bio-Techne Reports Q3 2026 Results, Net Sales Decline Slightly

Bio-Techne Corporation's Q3 2026 results show a slight decrease in net sales and a dip in operating income, attributed to product mix and prior year non-recurring items.

Summary

• Bio-Techne Corporation reported net sales of $311.4 million for the third quarter ended March 31, 2026, a 2% decrease from the prior year period. For the nine months ended March 31, 2026, net sales were $893.8 million, a 1% decrease.
• Gross margin for the quarter was 66.9%, down from 67.9% in the prior year. Adjusted gross margin was 70.4%, compared to 71.6% in the prior year.
• Operating income for the quarter was $75.5 million, a significant increase from $38.7 million in the prior year, driven by lower operating expenses, including a reduction in selling, general, and administrative costs.
• Net earnings for the quarter were $51.0 million, or $0.32 per diluted share, compared to $22.6 million, or $0.14 per diluted share, in the prior year.
• The company ended the quarter with $209.8 million in cash and cash equivalents.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but generally stable performance, with positives in profitability and cash flow offset by slight revenue declines and margin pressures.

Positives

• Significant increase in operating income to $75.5 million from $38.7 million in the prior year, primarily due to reduced operating expenses.
• Diluted earnings per share increased to $0.32 from $0.14 in the prior year.
• Strong cash generation from operating activities, totaling $196.7 million for the nine months ended March 31, 2026.
• The Diagnostics and Spatial Biology segment showed positive organic growth of 3% for both the quarter and nine months, with an improved operating margin of 12.1% for the quarter.
• Cost management initiatives appear to be effective, leading to a decrease in SG&A expenses.

Negatives

• Consolidated net sales decreased by 2% to $311.4 million for the quarter and 1% to $893.8 million for the nine months.
• Protein Sciences segment net sales decreased 1% for the quarter and remained flat for the nine months, with organic revenue down 4% for the quarter.
• Gross margin decreased to 66.9% from 67.9% in the prior year quarter.
• Adjusted gross margin also saw a decline to 70.4% from 71.6% in the prior year quarter.
• The company is facing ongoing restructuring costs, with $2.8 million incurred in the quarter and $6.3 million for the nine months.

Risks

• The outcomes of legal actions are not within the Company's complete control and could have a material adverse impact on consolidated earnings, financial position, and/or cash flows.
• Future gross margins are expected to be impacted by the differing growth rates of various portfolio segments.
• The company faces competition, general economic conditions, regulatory changes, and supply chain challenges, as detailed in its Form 10-K.

Future Outlook

The company expects its consolidated income tax rate for the remainder of fiscal 2026 to range from 25% to 29%, excluding discrete items. Management expects to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future through currently available cash, cash generated from operations, and remaining credit available on its existing revolving line of credit.

Management Comments

• The company is committed to providing the life sciences community with innovative, high-quality scientific tools that allow customers to make extraordinary discoveries and treat and diagnose diseases.
• Strategic pillars for long-term growth and profitability include growing and leveraging the core, capitalizing on high potential markets, market expansion through innovation and acquisition, delivering best-in-class customer experience, and developing people through a transformative culture.
• Management continues to make strategic growth investments in research and development while employing cost management initiatives.

Industry Context

StockSavvy.ai notes that Bio-Techne's performance in the life sciences and diagnostics market reflects broader industry trends of increased investment in research and development, alongside a focus on operational efficiency and margin improvement.

Comparison to Industry Standards

• The reported gross margin of 66.9% is generally strong for the biotechnology sector, though slightly lower than the prior year's 67.9%.
• The increase in operating income, despite a slight revenue dip, suggests effective cost control, a key performance indicator in the competitive life sciences tools market.
• The company's focus on both Protein Sciences and Diagnostics & Spatial Biology segments aligns with industry diversification strategies to mitigate risks and capture growth in different market segments.

Legal Proceedings

• As of May 6, 2026, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company's business, results of operations, financial condition or cash flows.

Stakeholder Impact

• Shareholders may see continued dividend payments, with the next $0.08 per share dividend expected.
• Employees may be impacted by ongoing restructuring activities, though specific details are not provided.
• Customers in the research and clinical diagnostic markets will continue to be served by the company's product portfolio.

Next Steps

• Continue to execute strategies focused on growing and leveraging the core business.
• Capitalize on high-potential markets and expand market presence through innovation and acquisition.
• Deliver a best-in-class customer experience.
• Develop people through a transformative culture.
• The company expects to incur restructuring costs through fiscal 2027.
• The second part of the Wilson Wolf forward contract, requiring acquisition of the remaining 80.1% interest, is forecasted to occur between fiscal 2026 and fiscal 2028.

Key Dates

Recommendation

The company demonstrates solid operational execution with improved profitability and strong cash flow, but the slight decline in revenue and gross margins warrants a cautious approach. The absence of significant growth drivers in this report suggests a 'hold' rating until clearer signs of revenue acceleration emerge.

Keywords

Bio-Techne, 10-Q, Quarterly Report, Financial Results, Life Sciences, Biotechnology, Diagnostics, Protein Sciences, Spatial Biology, SEC Filing